Basel, Switzerland—Lonza announced in a press release the internal alignment of its business structure to accelerate growth along the Healthcare Continuum® and strengthen the Microbial Control business.
According to the release, Stefan Stoffel has been appointed to a new role on the Executive Committee as COO, responsible for operations beginning March 1st. He will cover Operations, Quality, Engineering, and Strategic Growth Initiatives across the LPBN segment.
The alignment, according to the press release, will enable both the segment dedicated to Lonza Specialty Ingredients and the segment dedicated to Lonza Pharma Biotech and Nutrition to focus on operational excellence, including an integrated global asset strategy that enables a more-cohesive supply chain and asset utilization.
Incoming Group CEO Marc Funk commented on the announcement: “Our new structure will nurture synergies and increase operational efficiency, which will create customer benefits. More importantly, it will enable Lonza to develop a more compelling offer across pharma, biotech, and nutrition, and to extend our competitive advantage in the market. Stefan is a well-regarded, long-established and strong leader in the Lonza business. His oversight of LPBN segment operations will help us to galvanize our offering and capitalize on future opportunities.”
The release says that Lonza is now positioned to leverage its innovation programs and technology platforms to create new solutions at the food-pharma convergence and in microbial control.